Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1α

Neoplasia

Volumn 12, Issue 7, 2010, Pages 539-549

  Paone, Alessio ^a   Galli, Roberta ^a   Gabellini, Chiara ^b   Lukashev, Dmitriy ^c   Starace, Donatella ^a   Gorlach, Agnes ^d   de Cesaris, Paola ^e   Ziparo, Elio ^a   del Bufalo, Donatella ^b   Sitkovsky, Michail V ^c   Filippini, Antonio ^a   Riccioli, Anna ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NORTHEASTERN UNIVERSITY   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; VASCULOTROPIN; TLR3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL AGGREGATION; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MORPHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; AGONISTS; APOPTOSIS; CELL CULTURE; CELL HYPOXIA; DRUG EFFECTS; GENETICS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SECRETION (PROCESS); TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLY I-C; PROSTATIC NEOPLASMS; TOLL-LIKE RECEPTOR 3; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954995650     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.92106     Document Type: Article

References (53)

1. Pugh CW, Tan CC, Jones RW, and Ratcliffe PJ (1991). Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci USA 88, 10553-10557.
2. Semenza GL, Nejfelt MK, Chi SM, and Antonarakis SE (1991). Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 88, 5680-5684.
3. Wenger RH, Stiehl DP, and Camenisch G (2005). Integration of oxygen signaling at the consensus HRE. Sci STKE 2005, rel2.
4. Brahimi-Horn MC and Pouyssegur J (2009). HIF at a glance. J Cell Sci 122, 1055-1057.
5. Depping R, Hagele S, Wagner KF, Wiesner RJ, Camenisch G, Wenger RH, and Katschinski DM (2004). A dominant-negative isoform of hypoxia-inducible factor-lα specifically expressed in human testis. Biol Reprod 71, 331-339.
6. Lukashev D and Sitkovsky M (2008). Preferential expression of the novel alternative isoform 1.3 of hypoxia-inducible factor lα in activated human T lymphocytes. Hum Immunol 69, 421-425.
7. Dery MA, Michaud MD, and Richard DE (2005). Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37, 535-540.
8. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al. (2008). High expression of HIF lα is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF Neoplasia 10, 674-679.
9. Kimbro KS and Simons JW (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13, 739-749.
10. Zhong H, Semenza GL, Simons JW, and De Marzo AM (2004). Up-regulation of hypoxia-inducible factor lα is an early event in prostate carcinogenesis. Cancer Detect Prev 28, 88-93.
11. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, and Simons JW (1999). Overexpression of hypoxia-inducible factor lα in common human cancers and their metastases. Cancer Res 59, 5830-5835.
12. Gomella LG, Johannes J, and Trabulsi EJ (2009). Current prostate cancer treatments: effect on quality of life. Urology 73, S28-S35.
13. Brune B and Zhou J (2003). The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-lα (HIF-lα). Curr Med Chem 10, 845-855.
14. Gorlach A and Kietzmann T (2007). Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods Enzymol 435, 421-446.
15. Gerber SA and Pober JS (2008). IFN-α induces transcription of hypoxia-inducible factor-lα to inhibit proliferation of human endothelial cells. J Immunol 181, 1052-1062.
16. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, and Neckers L (2003). Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kB activation. Biochem J 370, 1011-1017.
17. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, and Cohen B (1998). Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-lα/ARNT. EMBO J17, 5085-5094.
18. Lukashev D, Caldwell C, Ohta A, Chen P, and Sitkovsky M (2001). Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-lα in activated T lymphocytes. J Biol Chem 276, 48754-48763.
19. Blouin CC, Page EL, Soucy GM, and Richard DE (2004). Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor lα. Blood 103, 1124-1130.
20. Nicholas SA and Sumbayev W (2009). The involvement of hypoxia-inducible factor 1 α in Toll-like receptor 7/8-mediated inflammatory response. Cell Res 19, 973-983.
21. Ramanathan M, Luo W, Csoka B, Hasko G, Lukashev D, Sitkovsky MV, and Leibovich SJ (2009). Differential regulation of HIF-lα isoforms in murine macrophages by TLR4 and adenosine A(2A) receptor agonists. Jleukoc BiolH6,681-689.
22. Srikrishna G and Freeze HH (2009). Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11, 615-628.
23. Akira S, Uematsu S, and Takeuchi O (2006). Pathogen recognition and innate immunity. Cell 124, 783-801.
24. Iwasaki A and Medzhitov R (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5, 987-995.
25. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, and Xiong H (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65, 5009-5014.
26. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T and Mor G (2006). TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66, 3859-3868.
27. Paone A, StaraceD, GalliR, PadulaF, DeCP, Filippini A, Ziparo E, andRiccioliA (2008). Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism. Carcinogenesis 29, 1334-1342.
28. Salaun B, Coste I, Rissoan MC, Lebecque SJ, and Renno T (2006). TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176, 4894-4901.
29. Salaun B, Lebecque S, Matikainen S, Rimoldi D, and Romero P (2007). Tolllike receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13, 4565-4574.
30. Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L, and Zhou Q (2009). BCI-xI is a target gene regulated by hypoxia-inducible factor-lα. J Biol Chem 284, 10004-10012.
31. Peng XH, Kama P, Cao Z, Jiang BH, Zhou M, and Yang L (2006). Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-lα signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281, 25903-25914.
32. Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M, and Michiels C (2005). Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280, 9336-9344.
33. Bonello S, Zahringer C, Belaiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, and Gorlach A (2007). Reactive oxygen species activate the HIF-lα promoter via a functional NFkB site. Arterioscler Thromb Vase Biol27, 755-761.
34. Gorlach A (2009). Regulation of HIF-lα at the transcriptional level. Curr Pharm Des 15, 3844-3852.
35. Nicholas SA and Sumbayev W (2010). The role of redox-dependent mechanisms in the downregulation of ligand-induced Toll-like receptors 7, 8 and 4-mediated HIF-1 α prolyl hydroxylation. Immunol Cell Biol HH, 180-186.
36. Clemens MJ, Hershey JW, Hovanessian AC, Jacobs BC, Katze MG, Kaufman RJ, Lengyel P, Samuel CE, Sen GC, and Williams BR (1993). PKR: proposed nomenclature for the RNA-dependent protein kinase induced by interferon. J Interferon Res 13, 241.
37. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, and Fujita T (2004). The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5, 730-737.
38. Zliong H, Agani F, Baccala AA, Laugliner E, Rioseco-Camacho N, Isaacs WB, Simons JW, and Semenza GL (1998). Increased expression of hypoxia inducible factor-lα in rat and human prostate cancer. Cancer Res 58, 5280-5284.
39. Thomas R and Kim MH (2008). HIF-lα: a key survival factor for serum-deprived prostate cancer cells. Prostate 68, 1405-1415.
40. Greijer AE and van der Wall E (2004). The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57, 1009-1014.
41. Hong SW, Yoo JW, Kang HS, Kim S, and Lee DK (2009). HIF-lα-dependent gene expression program during the nucleic acid-triggered antiviral innate immune responses. Mol Cells 27, 243-250.
42. Jasani B, Navabi H, and Adams M (2009). Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27, 3401-3404.
43. Conroy H, Marshall NA, and Mills KH (2008). TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27, 168-180.
44. Wolska A, Lech-Maranda E, and Robak T (2009). Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett 14, 248-272.
45. Lorenzo PI and Saatcioglu F (2008). Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 10, 418-428.
46. Zhou J, Schmid T, Schnitzer S, and Brune B (2006). Tumor hypoxia and cancer progression. Cancer Lett 237', 10-21.
47. Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2, 795-803.
48. Wornle M, Sauter M, Kastenmuller K, Ribeiro A, Roeder M, Mussack T, LadurnerR, and SitterT (2009). Roleofviral induced vascular endothelial growth factor (VEGF) production in pleural effusion and malignant mesothelioma. Cell BiolLnt33, 180-186.
49. Wenger RH, Rolfs A, Spielmann P, Zimmermann DR, and Gassmann M (1998). Mouse hypoxia-inducible factor-1α is encoded by two different mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter. Blood 91, 3471-3480.
50. Iyer NY Leung SW and Semenza GL (1998). The human hypoxia-inducible factor lα gene: HIF1A structure and evolutionary conservation. Genomics 52, 159-165.
51. Melillo G (2007). Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26, 341-352.
52. Onnis B, Rapisarda A, and Melillo G (2009). Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13, 2780-2786.
53. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, et al. (2009). Endothelial NOS, estrogen receptor p, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119, 1093-1108.